Organogenesis Holdings Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Organogenesis Holdings Inc. entered into an At-the-Market (ATM) sales agreement dated August 6, 2026, with BTIG LLC and Citizens JMP Securities LLC to sell up to $75,000,000 of Class A Common Stock on a delayed or continuous basis under its existing Form S-3 shelf registration (File No. 333-281392, declared effective August 15, 2024). The agents will receive up to 3.0% commission on gross proceeds. No shares have been sold as of the filing date; the agreement permits future sales subject to market conditions and regulatory compliance.
Why this rating
ATM agreements are routine equity financing tools. $75M cap is ~25% of $299M market cap—material if fully deployed, but typical for a smaller public company maintaining capital flexibility. No actual dilution or capital raised yet; agreement is prospective only.
Extracted items
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.